WallStSmart
MREO

Mereo BioPharma Group PLC ADR

NASDAQ: MREO · HEALTHCARE · BIOTECHNOLOGY

$0.27
-2.89% today

Updated 2026-04-30

Market cap
$44.72M
P/E ratio
P/S ratio
89.45x
EPS (TTM)
$-0.25
Dividend yield
52W range
$0 – $3
Volume
1.6M

Mereo BioPharma Group PLC ADR (MREO) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$0.00$-3.29M$0.00$-122000.00$393000.00$49.21M$1.51M$10.00M$0.00$500000.00
Revenue growth (YoY)+100.0%+422.1%+12422.4%-96.9%+563.6%-100.0%
Cost of revenue$0.00$24.56M$34.61M$22.70M$2.01M$2.05M$24.17M$-257442.00$2.57M$1.09M$133000.00
Gross profit$0.00$-24.56M$-37.89M$-22.70M$-2.01M$-2.05M$25.04M$257442.00$7.43M$-1.09M$367000.00
Gross margin1153.4%1649.0%-521.8%50.9%17.1%74.3%73.4%
R&D$214.40M$24.56M$34.61M$22.70M$30.12M$20.96M$31.80M$30.75M$17.42M$20.93M$17.77M
SG&A$7.67M$11.62M$10.70M$12.50M$15.91M$21.22M$21.50M$19.54M$18.42M$26.43M$23.01M
Operating income$-13.16M$-36.18M$-45.30M$-35.21M$-50.41M$-48.18M$-28.26M$-53.67M$-28.42M$-47.36M$-40.50M
Operating margin1379.0%41322.4%-12258.7%-57.4%-3561.2%-284.2%-8100.3%
EBITDA$-38.41M$-44.44M$-34.86M$-44.57M$-203.41M$25.49M$-39.98M$-26.06M$-40.80M$-39.35M
EBITDA margin1352.7%36531.1%-51759.2%51.8%-2652.9%-260.6%-7869.9%
EBIT$-518.24M$-38.44M$-44.48M$-34.90M$-46.58M$-205.46M$24.62M$-40.87M$-27.12M$-41.88M$-40.50M
Interest expense$0.00$179765.00$1.09M$2.36M$3.50M$6.38M$5.22M$3.36M$2.88M$1.37M$255595.00
Income tax$-1.14M$-5.33M$-8.15M$-5.28M$-8.00M$-3.62M$2.05M$-2.34M$-532000.00$18200.00
Effective tax rate8.5%15.8%17.4%14.1%15.3%1.7%10.6%5.3%1.8%-0.0%0.0%
Net income$-12.19M$-28.39M$-38.80M$-32.03M$-44.45M$-209.83M$17.17M$-42.12M$-29.47M$-43.25M$-41.88M
Net income growth (YoY)-132.9%-36.7%+17.4%-38.8%-372.0%+108.2%-345.3%+30.0%-46.8%+3.2%
Profit margin1181.0%36435.9%-53391.6%34.9%-2795.1%-294.7%-8375.6%